x

Posted 30 March, 2023

Nkarta, Inc. appointed new CEO

CEO Change detected for ticker Nasdaq:NKTX in a 8-K filed on 30 March, 2023.


  On March 28, 2023, Dr. Nadir Mahmood notified Nkarta, Inc. (the "Company") of his decision to resign as Chief Financial and Business Officer of the Company to take a position as chief executive officer of a private biotechnology company.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Nkarta, Inc.
Health Care/Life Sciences • Biotechnology
Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firm’s product include NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes, and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.
Market Cap
$116M
View Company Details
Nkarta, Inc. by TradingView
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers. Compensatory Arrangements of Certain Officers.


On March 28, 2023, Dr. Nadir Mahmood notified Nkarta, Inc. (the "Company") of his decision to resign as Chief Financial and Business Officer of the Company to take a position as chief executive officer of a private biotechnology company. Dr. Mahmood's resignation is effective June 30, 2023.